Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Antibodies against transcriptional intermediary factor (TIF)-1? are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1? antibodies in DM is a high priority for both patient diagnosis and risk assessment.We sought to define the clinical phenotype of patients with anti-TIF-1? DM.Using a novel, sensitive, and specific assay for anti-TIF-1? antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1? antibodies and particular clinical and laboratory features.In all, 55 (41%) patients had autoantibodies to TIF-1?. Anti-TIF-1? positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1? autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic ("red on white") patches.This was a retrospective study from a single tertiary referral center.TIF-1? is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1? positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.
View details for DOI 10.1016/j.jaad.2014.12.009
View details for PubMedID 25595720